Advanced Enzyme Technologies: The financial results for the period ended September 30, 2026
Advanced Enzyme Technologies (ADVENZYMES) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹2,958 crore.
What happened
Advanced Enzyme Technologies (ADVENZYMES) filed a disclosure with the exchanges on 31 October 2026 at 12:46 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Advanced Enzyme Technologies is a small-cap company in the Healthcare sector, with a market value of about ₹2,958 crore.
The stock last traded at ₹264.2, against a 52-week range of ₹246.8–₹419 (37.0% below the high).
Before this filing the shares had moved −6.4% over the month and −16.2% over three months. Average daily turnover over the last 20 sessions was about ₹5.52 crore.
Promoters held 43.24% at the end of Q1 FY27, down 0.02% points from the previous quarter. Foreign institutions owned 26.71% and domestic institutions 4.78%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 186 | 39.9 | 3.57 |
| Q2 FY26 | 185 | 43.3 | 3.87 |
| Q3 FY26 | 172 | 42.5 | 3.8 |
| Q4 FY26 | 203 | 43 | 3.84 |
| Q1 FY27 | 190 | 37.1 | 3.31 |
What history shows
BCEIE's records show 1 previous results filing from the company since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +1.3% on average the next day and +2.0% over five days; 57% of them rose the next day.
Market-wide, 10,104 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 31 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Advanced Enzyme Tech closes buyback, acquires 24.11 lakh shares for ₹69.7 Cr
- Advanced Enzyme Technologies (ADVENZYMES.NS) Slips 1.87% to ₹262.0 as Stock Retreats From Upper Range - Gap Down Bounce Plays
- Advanced Enzyme Technologies ADVENZYMES Buyback Closure
- Advanced Enzyme Technologies (NSE:ADVENZYMES): Promoter Group Member Seeks Public Shareholder Reclassification
- Advanced Enzyme Technologies announces financial results for the quarter and half year ended September 30, 2026
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.